HYFT
ImmunoPrecise Antibodies Ltd.
1.50$
+11.2%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 67.1% | 37.9% | 30.8% | 73.5% | 30.4% | 5.7% | 8.1% | 46.5% | 60.1% | 16.9% | 3.3% | 9.6% | 10.7% | 1.6% | 96.8% | 92.8% | 89.1% | 97.2% | 93.6% | 88.2% | 83.6% | 19.5% | 34.8% | 28.2% | 73.0% | 40.1% | 21.6% | 19.1% | 42.2% | 75.9% | |
| 9.2% | 30.1% | 24.6% | 23.2% | 6.8% | 3.0% | 5.6% | 37.0% | 59.3% | 0.7% | 1.8% | 3.9% | 4.6% | 1.1% | 26.4% | 19.9% | 28.5% | 28.5% | 8.4% | 24.7% | 65.6% | 7.3% | 19.3% | 9.6% | 62.4% | 32.1% | 10.6% | 5.8% | 24.0% | 53.1% | |
| 66.5% | 36.9% | 25.2% | 25.5% | 7.6% | 3.9% | 5.6% | 37.0% | 59.3% | 1.0% | 2.8% | 8.8% | 5.1% | 1.4% | 88.6% | 68.2% | 66.0% | 95.8% | 87.0% | 40.2% | 65.6% | 7.3% | 19.3% | 9.6% | 62.4% | 32.1% | 10.6% | 5.8% | 24.0% | 53.1% | |
| 0.2% | 0.4% | 0.3% | 0.4% | 21.4% | 0.4% | 1.4% | 8.4% | 0.5% | 0.2% | 0.1% | 0.4% | 0.6% | 0.1% | 5.5% | 23.6% | 21.2% | 0.7% | 4.3% | 32.7% | 11.9% | 9.0% | 6.9% | 13.4% | 5.4% | 3.6% | 5.0% | 6.8% | 10.8% | 16.8% | |
| – | – | – | – | – | – | – | – | – | 0.3% | – | – | – | – | – | – | – | – | – | 0.2% | 1.5% | 1.7% | 7.5% | 3.0% | 1.8% | 1.7% | 2.6% | 3.6% | 4.7% | 2.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 19.9% | 29.1% | 29.0% | 11.6% | 21.1% | 24.6% | 12.8% | 18.5% | 0.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 2.9% | – | – | 16.4% | 29.7% | 30.4% | 9.0% | 34.6% | 39.7% | 39.3% | 2.4% | – | |
| 6.4% | 2.3% | 2.2% | 2.5% | 77.4% | 21.3% | 1.7% | 3.5% | 1.1% | 3.4% | 2.8% | 0.7% | 2.2% | 1.8% | 40.4% | 228.6% | 531.5% | 213.3% | 552.2% | 34.2% | 21.3% | 48.3% | 36.3% | 44.7% | 15.0% | 19.6% | 25.7% | 43.5% | 46.8% | 45.0% | |
| 6.4% | 2.3% | 2.2% | 2.5% | 77.4% | 21.3% | 1.7% | 3.5% | 1.1% | 3.4% | 2.8% | 0.7% | 2.2% | 1.8% | 40.4% | 228.6% | 531.5% | 213.3% | 552.2% | 27.9% | 21.3% | 17.4% | 25.4% | 29.1% | 9.1% | 9.9% | 7.6% | 13.5% | 20.3% | 27.1% | |
| – | – | – | – | – | – | 0.8% | – | – | – | – | – | – | – | – | 53.6% | 100.1% | 86.4% | 160.4% | – | – | 0.8% | 10.0% | 10.5% | 2.7% | 2.5% | 2.5% | 2.6% | 4.2% | 2.1% | |
| 2.8% | 2.3% | 2.2% | 2.5% | 14.8% | 3.4% | 0.9% | 3.5% | 1.1% | 3.3% | 2.8% | 0.7% | – | – | 52.2% | 175.0% | 431.5% | 126.9% | 391.8% | 7.3% | 16.9% | 8.3% | 5.6% | 5.0% | 2.0% | 5.1% | 3.2% | 7.3% | 11.9% | 19.5% | |
| 93.6% | 97.7% | 97.8% | 97.5% | 22.6% | 78.7% | 98.3% | 96.5% | 98.9% | 96.6% | 97.2% | 99.3% | 97.8% | 98.2% | 59.6% | -128.6% | -431.5% | -113.3% | -452.2% | 65.8% | 78.7% | 51.7% | 63.7% | 55.3% | 85.0% | 80.5% | 74.3% | 56.5% | 53.2% | 55.0% | |
| -159.1% | -236.5% | -494.1% | -2,318.1% | -824.9% | -1,114.1% | -1,090.3% | -736.9% | -253.4% | -263.5% | -199.6% | -229.2% | -177.4% | -244.4% | -8,814.9% | -20,212.7% | -37,894.6% | -13,260.1% | -41,046.7% | 65.8% | -116.2% | -39.6% | -61.7% | -82.5% | -44.5% | -49.8% | -93.9% | -167.1% | -289.8% | -667.8% | |
| 3.9% | 5.2% | 9.2% | 37.5% | 13.2% | 20.3% | 23.7% | 18.0% | 7.3% | 9.1% | 6.8% | 8.1% | 6.9% | 10.1% | 260.7% | 590.2% | 1,064.7% | 464.8% | 1,192.9% | 144.8% | 100.8% | 37.1% | 44.2% | 50.0% | 24.6% | 21.1% | 32.0% | 42.7% | 75.1% | 217.3% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.